Regulus Therapeutics (RGLS) Earnings Date, Estimates & Call Transcripts $8.16 0.00 (0.00%) As of 06/25/2025 Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Regulus Therapeutics Earnings Summary Regulus Therapeutics posted Q1 2025 earnings on May 8, 2025, reporting an EPS of -$0.15, which topped analysts' consensus estimates of -$0.29 by $0.14. With a trailing EPS of -$0.73, Regulus Therapeutics' earnings are expected to decrease next year, from ($0.88) to ($1.38) per share. Upcoming Q2 Earnings DateAug. 6Before Market OpensEstimatedConsensus EPS (May. 8) -$0.29 Actual EPS (May. 8) -$0.15 Beat By $0.14 Q1 2025 Earnings ResourcesQ1 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)RGLS Upcoming EarningsRegulus Therapeutics' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules. Powered by Get Regulus Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Regulus Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRGLS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Regulus Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.23-$0.23-$0.23Q2 20252-$0.27-$0.23-$0.25Q3 20252-$0.31-$0.24-$0.28Q4 20252-$0.34-$0.20-$0.27 Regulus Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/6/2025(Estimated)--------5/8/2025Q1 2025-$0.29-$0.15+$0.14-$0.15--3/20/2025Q4 2024-$0.20-$0.20--$0.20--11/7/2024Q3 2024-$0.18-$0.21 -$0.03-$0.21--8/8/2024--$0.17-$0.17--$0.17--5/9/2024Q1 2024-$0.15-$0.29 -$0.14-$0.29--3/21/2024Q4 2023-$0.40-$0.40--$0.40--11/9/2023Q3 2023-$0.36-$0.40 -$0.04-$0.40--8/8/2023Q2 2023-$0.39-$0.37+$0.02-$0.37-- Regulus Therapeutics Earnings - Frequently Asked Questions When is Regulus Therapeutics' earnings date? Regulus Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 6th, 2025 based off last year's report dates. Learn more on RGLS's earnings history. Did Regulus Therapeutics beat their earnings estimates last quarter? In the previous quarter, Regulus Therapeutics (NASDAQ:RGLS) reported ($0.15) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.29) by $0.14. Learn more on analysts' earnings estimate vs. RGLS's actual earnings. How much profit does Regulus Therapeutics generate each year? Regulus Therapeutics (NASDAQ:RGLS) has a recorded net income of -$46.36 million. RGLS has generated -$0.73 earnings per share over the last four quarters. What is Regulus Therapeutics' EPS forecast for next year? Regulus Therapeutics' earnings are expected to decrease from ($0.88) per share to ($1.38) per share in the next year. More Earnings Resources from MarketBeat Related Companies Ligand Pharmaceuticals Earnings Date BioCryst Pharmaceuticals Earnings Date Amicus Therapeutics Earnings Date Celldex Therapeutics Earnings Date Innoviva Earnings Date Dynavax Technologies Earnings Date MannKind Earnings Date OPKO Health Earnings Date Novavax Earnings Date Geron Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs This page (NASDAQ:RGLS) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredNobel Prize Material Finally Goes CommercialA Nobel Prize–winning material just got its biggest breakthrough in 30 years. A little-known company has cr...True Market Insiders | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
